252 related articles for article (PubMed ID: 34199285)
61. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
[TBL] [Abstract][Full Text] [Related]
62. Exosomes in multiple myeloma: from bench to bedside.
Menu E; Vanderkerken K
Blood; 2022 Dec; 140(23):2429-2442. PubMed ID: 35271699
[TBL] [Abstract][Full Text] [Related]
63. Tumor-derived extracellular vesicles inhibit osteogenesis and exacerbate myeloma bone disease.
Zhang L; Lei Q; Wang H; Xu C; Liu T; Kong F; Yang C; Yan G; Sun L; Zhao A; Chen W; Hu Y; Xie H; Cao Y; Fu F; Yuan G; Chen Z; Guo AY; Li Q
Theranostics; 2019; 9(1):196-209. PubMed ID: 30662562
[No Abstract] [Full Text] [Related]
64. Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes.
Colombo M; Mirandola L; Platonova N; Apicella L; Basile A; Figueroa AJ; Cobos E; Chiriva-Internati M; Chiaramonte R
Leukemia; 2013 Apr; 27(5):1009-18. PubMed ID: 23307030
[TBL] [Abstract][Full Text] [Related]
65. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
Lee HT; Kim Y; Park UB; Jeong TJ; Lee SH; Heo YS
Biochem Biophys Res Commun; 2021 Jan; 536():26-31. PubMed ID: 33360095
[TBL] [Abstract][Full Text] [Related]
66. Extracellular Vesicles Improve Post-Stroke Neuroregeneration and Prevent Postischemic Immunosuppression.
Doeppner TR; Herz J; Görgens A; Schlechter J; Ludwig AK; Radtke S; de Miroschedji K; Horn PA; Giebel B; Hermann DM
Stem Cells Transl Med; 2015 Oct; 4(10):1131-43. PubMed ID: 26339036
[TBL] [Abstract][Full Text] [Related]
67. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.
An G; Acharya C; Feng X; Wen K; Zhong M; Zhang L; Munshi NC; Qiu L; Tai YT; Anderson KC
Blood; 2016 Sep; 128(12):1590-603. PubMed ID: 27418644
[TBL] [Abstract][Full Text] [Related]
68. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
[TBL] [Abstract][Full Text] [Related]
69. [Current status and future prospects of immunotherapy for multiple myeloma].
Imai Y
Rinsho Ketsueki; 2021; 62(5):407-417. PubMed ID: 34108322
[TBL] [Abstract][Full Text] [Related]
70. Extracellular Vesicles Derived From Adult and Fetal Bone Marrow Mesenchymal Stromal Cells Differentially Promote
Ghebes CA; Morhayim J; Kleijer M; Koroglu M; Erkeland SJ; Hoogenboezem R; Bindels E; van Alphen FPJ; van den Biggelaar M; Nolte MA; van der Eerden BCJ; Braakman E; Voermans C; van de Peppel J
Front Bioeng Biotechnol; 2021; 9():640419. PubMed ID: 33718342
[TBL] [Abstract][Full Text] [Related]
71. Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.
Binsfeld M; Muller J; Lamour V; De Veirman K; De Raeve H; Bellahcène A; Van Valckenborgh E; Baron F; Beguin Y; Caers J; Heusschen R
Oncotarget; 2016 Jun; 7(25):37931-37943. PubMed ID: 27177328
[TBL] [Abstract][Full Text] [Related]
72. microRNA-148a-3p in extracellular vesicles derived from bone marrow mesenchymal stem cells suppresses SMURF1 to prevent osteonecrosis of femoral head.
Huang S; Li Y; Wu P; Xiao Y; Duan N; Quan J; Du W
J Cell Mol Med; 2020 Oct; 24(19):11512-11523. PubMed ID: 32871042
[TBL] [Abstract][Full Text] [Related]
73. Communication between stromal and hematopoietic stem cell by exosomes in normal and malignant bone marrow niche.
Niazi V; Parseh B; Ahani M; Karami F; Gilanchi S; Atarodi K; Soufi M; Soleimani M; Ghafouri-Fard S; Taheri M; Zali H
Biomed Pharmacother; 2020 Dec; 132():110854. PubMed ID: 33059261
[TBL] [Abstract][Full Text] [Related]
74. piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment.
Li B; Hong J; Hong M; Wang Y; Yu T; Zang S; Wu Q
Oncogene; 2019 Jun; 38(26):5227-5238. PubMed ID: 30890754
[TBL] [Abstract][Full Text] [Related]
75. Extracellular vesicles as regulators of tumor fate: crosstalk among cancer stem cells, tumor cells and mesenchymal stem cells.
Lindoso RS; Collino F; Vieyra A
Stem Cell Investig; 2017; 4():75. PubMed ID: 29057247
[TBL] [Abstract][Full Text] [Related]
76. Actors on the Scene: Immune Cells in the Myeloma Niche.
Leone P; Solimando AG; Malerba E; Fasano R; Buonavoglia A; Pappagallo F; De Re V; Argentiero A; Silvestris N; Vacca A; Racanelli V
Front Oncol; 2020; 10():599098. PubMed ID: 33194767
[TBL] [Abstract][Full Text] [Related]
77. Endosteal and Perivascular Subniches in a 3D Bone Marrow Model for Multiple Myeloma.
Braham MVJ; Ahlfeld T; Akkineni AR; Minnema MC; Dhert WJA; Öner FC; Robin C; Lode A; Gelinsky M; Alblas J
Tissue Eng Part C Methods; 2018 May; 24(5):300-312. PubMed ID: 29652626
[TBL] [Abstract][Full Text] [Related]
78. Comprehensive landscape of extracellular vesicle-derived RNAs in cancer initiation, progression, metastasis and cancer immunology.
Hu W; Liu C; Bi ZY; Zhou Q; Zhang H; Li LL; Zhang J; Zhu W; Song YY; Zhang F; Yang HM; Bi YY; He QQ; Tan GJ; Sun CC; Li DJ
Mol Cancer; 2020 Jun; 19(1):102. PubMed ID: 32503543
[TBL] [Abstract][Full Text] [Related]
79. Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.
Accardi F; Toscani D; Bolzoni M; Dalla Palma B; Aversa F; Giuliani N
Biomed Res Int; 2015; 2015():172458. PubMed ID: 26579531
[TBL] [Abstract][Full Text] [Related]
80. Effect of the extracellular component of bone marrow mesenchymal stromal cells from healthy donors on hematologic neoplasms and their angiogenesis.
Gladkova N; Umezu T; Imanishi S; Kawana C; Ohyashiki JH; Ohyashiki K
Hum Cell; 2020 Jul; 33(3):599-609. PubMed ID: 32281045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
